Bioiberica to present new approaches to the study of osteoarthritis at the 2019 Congress of the Spanish Society of Rheumatology
- Bioiberica will present two posters with novel data on the influence of various osteoarthritis drugs on the risk of virtual joint replacrement and systemic inflammation associated with this condition
- Our company will have their own booth at the exhibitors’ area, where they will present their portfolio of prescription products and dietary supplements for joint healthcare.
In Spain, approximately one out of every four adults suffers from a rheumatic condition-this means some 11 million people. Early diagnosis is essential to improve quality of life of these patients. The national congress of the Spanish Society of Rheumatology, held this week at Valencia’s Palacio de Congresos, has among its objectives to raise awareness on the importance of the early diagnosis of osteoarthritis.
On Friday, May 24, Dr. Marta Herrero, R&D Project leader in Human Health at Bioiberica, will be presenting two posters with novel data on the treatment of osteoarthritis.
The first poster presents a study determining the efficacy of a number of osteoarthritis drugs on the risk of virtual joint replacement- this is an index that measures parameters associated to pain, physical ability and structural changes in the joint.
The second poster presents a clinical study on the influence of a number of osteoarthritis drugs on systemic inflammation and catecholamine concentration in serum, factors related with the disease’s symptoms and progression.
Our company, with more than 40 years of experience in joint health, will have their own booth (#38) at the exhibitors’ area, where they will be presenting their portfolio of prescription products and dietary supplements for joint health.
